Records containing: Stage III Lung Non-Small Cell Cancer AJCC v7

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2026-04-21
Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
CLINICAL_TRIALS study record update · 2026-04-13
A Phase 1 Trial of MLN0128 (TAK-228) in Combination With Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
CLINICAL_TRIALS study record update · 2026-02-19
Local Consolidative Therapy (LCT) and Durvalumab (MEDI4736) for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (ENDURE)
CLINICAL_TRIALS study record update · 2024-08-21
A Phase 1B Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
CLINICAL_TRIALS study record update · 2024-07-30
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2023-05-06
A Phase 1 Study of Trametinib in Combination With Chemoradiation for KRAS Mutant Non-small Cell Lung Cancer
CLINICAL_TRIALS study record update · 2022-08-31
Phase I Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies With Defined Subsets of Autologous T Cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor
CLINICAL_TRIALS study record update · 2022-06-30
A Phase I Study of Methoxyamine Combined With Chemo-Radiation for Locally Advanced Non-Squamous Non-Small Cell Lung Cancer
CLINICAL_TRIALS study record update · 2021-07-12
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
CLINICAL_TRIALS study record update · 2020-04-06
A Phase II Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy